Enhanced in vivo osteogenesis by nanocarrier-fused bone morphogenetic protein-4

被引:28
|
作者
Shiozaki, Yasuyuki [1 ,2 ]
Kitajima, Takashi [4 ]
Mazaki, Tetsuro [1 ,2 ]
Yoshida, Aki [1 ]
Tanaka, Masato [1 ]
Umezawa, Akihiro [5 ]
Nakamura, Mariko [6 ]
Yoshida, Yasuhiro [3 ]
Ito, Yoshihiro [4 ]
Ozaki, Toshifumi [1 ]
Matsukawa, Akihiro [2 ]
机构
[1] Okayama Univ, Dept Orthoped Surg, Okayama 7008558, Japan
[2] Okayama Univ, Dept Pathol & Expt Med, Okayama 7008558, Japan
[3] Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Biomat, Okayama 7008558, Japan
[4] RIKEN, Nano Med Engn Lab, Wako, Saitama, Japan
[5] Natl Res Inst Child Hlth & Dev, Okura, Tokyo, Japan
[6] Kibi Int Univ, Jr Coll, Dept Hlth & Welf Program, Takahashi, Okayama, Japan
来源
基金
日本学术振兴会;
关键词
BMP4; bone repair; bone tissue engineering; osteogenesis; OSTEOBLAST DIFFERENTIATION; ALKALINE-PHOSPHATASE; MATRIX; COLLAGEN; FUSION; FIBRONECTIN; SPINE;
D O I
10.2147/IJN.S44124
中图分类号
TB3 [工程材料学];
学科分类号
0805 ; 080502 ;
摘要
Purpose: Bone defects and nonunions are major clinical skeletal problems. Growth factors are commonly used to promote bone regeneration; however, the clinical impact is limited because the factors do not last long at a given site. The introduction of tissue engineering aimed to deter the diffusion of these factors is a promising therapeutic strategy. The purpose of the present study was to evaluate the in vivo osteogenic capability of an engineered bone morphogenetic protein-4 (BMP4) fusion protein. Methods: BMP4 was fused with a nanosized carrier, collagen-binding domain (CBD), derived from fibronectin. The stability of the CBD-BMP4 fusion protein was examined in vitro and in vivo. Osteogenic effects of CBD-BMP4 were evaluated by computer tomography after intramedullary injection without a collagen-sponge scaffold. Recombinant BMP-4, CBD, or vehicle were used as controls. Expressions of bone-related genes and growth factors were compared among the groups. Osteogenesis induced by CBD-BMP4, BMP4, and CBD was also assessed in a bone-defect model. Results: In vitro, CBD-BMP4 was retained in a collagen gel for at least 7 days while BMP4 alone was released within 3 hours. In vivo, CBD-BMP4 remained at the given site for at least 2 weeks, both with or without a collagen-sponge scaffold, while BMP4 disappeared from the site within 3 days after injection. CBD-BMP4 induced better bone formation than BMP4 did alone, CBD alone, and vehicle after the intramedullary injection into the mouse femur. -Bone-related genes and growth factors were expressed at higher levels in CBD-BMP4-treated mice than in all other groups, including BMP4-treated mice. Finally, CBD-BMP4 potentiated more bone formation than did controls, including BMP4 alone, when applied to cranial bone defects without a collagen scaffold. Conclusion: Altogether, nanocarrier-CBD enhanced the retention of BMP4 in the bone, thereby promoting augmented osteogenic responses in the absence of a scaffold. These results suggest that CBD-BMP4 may be clinically useful in facilitating bone formation.
引用
收藏
页码:1349 / 1360
页数:12
相关论文
共 50 条
  • [1] Bone morphogenetic protein-4
    Leong, LM
    Brickell, PM
    INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY, 1996, 28 (12): : 1293 - 1296
  • [2] In vivo evidence of role of bone morphogenetic protein-4 in the mouse ovary
    Tanwar, Pradeep Singh
    O'Shea, Tim
    McFarlane, James R.
    ANIMAL REPRODUCTION SCIENCE, 2008, 106 (3-4) : 232 - 240
  • [3] Bone morphogenetic protein-4 and bone morphogenetic protein receptors expressions in the adult rat eye
    Maruyama-Koide, Yuka
    Mikawa, Sumiko
    Sasaki, Takeshi
    Sato, Kohji
    EUROPEAN JOURNAL OF HISTOCHEMISTRY, 2017, 61 (03): : 178 - 185
  • [4] Bone morphogenetic protein-4 control of pituitary pathophysiology
    Giacomini, Damiana
    Paez-Pereda, Marcelo
    Theodoropoulou, Marily
    Gerez, Juan
    Nagashima, Alberto Carbia
    Chervin, Alberto
    Berner, Silvia
    Labeur, Marta
    Refojo, Damian
    Renner, Ulrich
    Stalla, Gunter K.
    Arzt, Eduardo
    PITUITARY TODAY: MOLECULAR, PHYSIOLOGICAL AND CLINICAL ASPECTS, 2006, 35 : 22 - 31
  • [5] Bone morphogenetic protein-4, a novel modulator of melanogenesis
    Yaar, Mina
    Wu, Christina
    Park, Hee-Young
    Panova, Izabela
    Schutz, Gunther
    Gilchrest, Barbara A.
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2006, 281 (35) : 25307 - 25314
  • [6] A role for bone morphogenetic protein-4 in adipocyte development
    Bowers, Robert R.
    Lane, M. Daniel
    CELL CYCLE, 2007, 6 (04) : 385 - 389
  • [7] The identification of a heparin binding domain peptide from bone morphogenetic protein-4 and its role on osteogenesis
    Choi, Yoon Jung
    Lee, Jue Yeon
    Park, Jung Hyun
    Park, Jun Beom
    Suh, Jin Sook
    Choi, Young Suk
    Lee, Seung Jin
    Chung, Chong-Pyoung
    Park, Yoon Jeong
    BIOMATERIALS, 2010, 31 (28) : 7226 - 7238
  • [8] Interaction between soluble type I receptor for bone morphogenetic protein and bone morphogenetic protein-4
    Natsume, T
    Tomita, S
    Iemura, S
    Kinto, N
    Yamaguchi, A
    Ueno, N
    JOURNAL OF BIOLOGICAL CHEMISTRY, 1997, 272 (17) : 11535 - 11540
  • [9] Chondrogenesis, bone morphogenetic protein-4 and mesenchymal stem cells
    Miljkovic, N. D.
    Cooper, G. M.
    Marra, K. G.
    OSTEOARTHRITIS AND CARTILAGE, 2008, 16 (10) : 1121 - 1130
  • [10] CHROMOSOMAL ASSIGNMENT OF THE HUMAN GENE FOR BONE MORPHOGENETIC PROTEIN-4
    TABAS, JA
    HAHN, GV
    COHEN, RB
    SEAUNEZ, HN
    MODI, WS
    WOZNEY, JM
    ZASLOFF, M
    KAPLAN, FS
    CLINICAL ORTHOPAEDICS AND RELATED RESEARCH, 1993, (293) : 310 - 316